A federal judge in Philadelphia is set to break new ground as he implements the US Supreme Court’s (SCOTUS) reverse-payment ruling ahead of a February trial targeting pharma company Cephalon and four generic drug makers.

Stephen Kastenberg, a partner at Ballard Spahr who represents reverse-payment defendants but is not involved in this case, told PaRR that Goldberg’s latest ruling is interesting in two respects.

Related Practices